4.99
3.31%
0.16
After Hours:
4.88
-0.11
-2.20%
Eledon Pharmaceuticals Inc stock is traded at $4.99, with a volume of 384.96K.
It is up +3.31% in the last 24 hours and up +90.46% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$4.83
Open:
$4.82
24h Volume:
384.96K
Relative Volume:
1.26
Market Cap:
$288.54M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-0.8358
EPS:
-5.97
Net Cash Flow:
$-39.53M
1W Performance:
+39.00%
1M Performance:
+90.46%
6M Performance:
+107.05%
1Y Performance:
+305.69%
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com
ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia
ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum
Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha
Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch
Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia
Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times
Promising results for diabetes treatment with new drug - Investing.com India
Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from - GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan
Algorae Pharmaceuticals Plans Major Securities Issuance - MSN
Midday Stock Roundup: The Ensign Group Beats Q3 Expectations - Orange County Business Journal
ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com
ELDN stock soars to 52-week high, touches $3.35 amid surge By Investing.com - Investing.com South Africa
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India
Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa
Nantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Nantahala Capital Management LLC Acquires New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Eledon Pharmaceuticals initiates $75 million stock sale agreement By Investing.com - Investing.com Australia
Eledon Pharmaceuticals initiates $75 million stock sale agreement - Investing.com
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference - GlobeNewswire
ELDNEledon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Eledon Announces Completion of Enrollment in Phase 2 BESTOW - GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients - StockTitan
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Declines By 6.8% - MarketBeat
Analysts Issue Forecasts for Eledon Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:ELDN) - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Earn Q3 2024 Earnings of ($0.20) Per Share - Defense World
Vanguard Group Inc. Has $2 Million Stock Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail
2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360% - TradingView
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Eledon Pharmaceuticals Inc (ELDN-Q) QuotePress Release - The Globe and Mail
Eledon Expects to Restate Results, Delays Quarterly Report - MarketWatch
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results - GlobeNewswire
Eledon Pharmaceuticals (NASDAQ:ELDN) Stock Price Down 1.7% - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 1.7% - Defense World
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial - GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection - Yahoo Finance
Midday Stock Roundup: BJ’s Drops on Revenue Miss - Orange County Business Journal
4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):